79 related articles for article (PubMed ID: 9684410)
1. Melan A (MART-1): a new monoclonal antibody for malignant melanoma diagnosis.
Orchard GE
Br J Biomed Sci; 1998 Mar; 55(1):8-9. PubMed ID: 9684410
[No Abstract] [Full Text] [Related]
2. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.
Fetsch PA; Marincola FM; Filie A; Hijazi YM; Kleiner DE; Abati A
Cancer; 1999 Feb; 87(1):37-42. PubMed ID: 10096358
[TBL] [Abstract][Full Text] [Related]
3. [Clinical application of monoclonal antibodies to human malignant melanoma-associated antigens].
Kageshita T; Ishihara K
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1744-8. PubMed ID: 3899015
[TBL] [Abstract][Full Text] [Related]
4. [Subungual amelanotic superficial spreading melanoma: a case diagnosed with mouse monoclonal antibodies against human melanosome-associated antigens (HMSA)].
Yamana K; Maeda K; Akutsu Y; Jimbow K
Nihon Hifuka Gakkai Zasshi; 1987 Aug; 97(9):1015-23. PubMed ID: 3430796
[No Abstract] [Full Text] [Related]
5. Skin layer-specific Melan-A expression during progression of human cutaneous melanoma: implications for diagnostic applications of the marker.
Sztramska A; Dymerska D; Chwirot BW
Melanoma Res; 2008 Aug; 18(4):259-67. PubMed ID: 18626310
[TBL] [Abstract][Full Text] [Related]
6. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
7. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma.
Berset M; Cerottini JP; Guggisberg D; Romero P; Burri F; Rimoldi D; Panizzon RG
Int J Cancer; 2001 Jan; 95(1):73-7. PubMed ID: 11241315
[TBL] [Abstract][Full Text] [Related]
8. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
9. Ducking stray "magic bullets": a Melan-A alert.
Maize JC; Resneck JS; Shapiro PE; McCalmont TH; LeBoit PE
Am J Dermatopathol; 2003 Apr; 25(2):162-5. PubMed ID: 12652201
[No Abstract] [Full Text] [Related]
10. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens.
van Dinten LC; Pul N; van Nieuwpoort AF; Out CJ; Jager MJ; van den Elsen PJ
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):24-30. PubMed ID: 15623750
[TBL] [Abstract][Full Text] [Related]
11. High-molecular-weight keratin stain as a complement to Melan A stain.
Egbert BM; Rouse RV; Swetter SM
J Cutan Pathol; 2008 Dec; 35(12):1159. PubMed ID: 18976405
[No Abstract] [Full Text] [Related]
12. Reliability of diagnosis of melanoma in situ.
Megahed M; Schön M; Selimovic D; Schön MP
Lancet; 2002 Jun; 359(9321):1921-2. PubMed ID: 12057558
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
14. CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype.
Breza TS; Magro CM
J Cutan Pathol; 2005 Nov; 32(10):685-9. PubMed ID: 16293181
[TBL] [Abstract][Full Text] [Related]
15. Neoplastic meningitis in malignant melanoma: diagnosis with monoclonal antibodies.
Moseley RP; Davies AG; Bourne SP; Popham C; Carrel S; Monro P; Coakham HB
J Neurol Neurosurg Psychiatry; 1989 Jul; 52(7):881-6. PubMed ID: 2671265
[TBL] [Abstract][Full Text] [Related]
16. An osteoid variant of cutaneous melanoma in a dog detected by S100 and melan a markers.
Maliver P; Estrada M; Lagadic M; Mialot M; Manin S; Fontaine JJ
J Vet Med A Physiol Pathol Clin Med; 2004 Dec; 51(9-10):413-5. PubMed ID: 15610483
[TBL] [Abstract][Full Text] [Related]
17. Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor.
Fetsch PA; Fetsch JF; Marincola FM; Travis W; Batts KP; Abati A
Mod Pathol; 1998 Aug; 11(8):699-703. PubMed ID: 9720495
[TBL] [Abstract][Full Text] [Related]
18. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
19. Canine balloon and signet-ring cell melanomas: a histological and immunohistochemical characterization.
Cangul IT; van Garderen E; van der Linde-Sipman JS; van den Ingh TS; Schalken JA
J Comp Pathol; 2001; 125(2-3):166-73. PubMed ID: 11578133
[TBL] [Abstract][Full Text] [Related]
20. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
